Pharma: Page 50
-
José Baselga, prominent cancer researcher, dies at 61
The head of AstraZeneca's oncology R&D changed the paradigm of breast cancer care by helping bring the targeted treatments Herceptin and Perjeta to patients.
By Jacob Bell • March 22, 2021 -
Courtesy of AstraZeneca
EU, UK throw support behind AstraZeneca's vaccine amid reports of rare blood clots
The two drug regulators each believe the benefits of the shot outweigh the risks after investigating rare and unusual clotting events that have led more than 20 countries to halt vaccinations.
By Ben Fidler • March 18, 2021 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Retrieved from C-SPAN on February 24, 2021
Becerra confirmed as HHS secretary
The 50-49 vote in the Senate was almost entirely along party lines. The only Republican to cross the aisle was Sen. Susan Collins of Maine.
By Shannon Muchmore • March 18, 2021 -
Kendall Davis/BioPharma Dive
Gilead, still aiming at NASH, broadens an alliance with Novo
With positive safety data in hand, the partners will advance work pairing the diabetes medicine Ozempic with two experimental treatments to see if they can reverse the liver disease, which has proven a tough target for drugmakers.
By Jonathan Gardner • March 18, 2021 -
Courtesy of Walmart
Biden administration hikes Medicare reimbursement for coronavirus vaccines
The increased payout by Medicare is intended to speed up distribution of the three currently available shots.
By Shannon Muchmore • March 16, 2021 -
Brian Tucker/BioPharma Dive
FTC joins overseas antitrust regulators in reexamination of pharma M&A
Rebecca Kelly Slaughter, the commission's acting chair, indicated future reviews could look beyond measures of company size and market share.
By Jonathan Gardner • March 16, 2021 -
Courtesy of Eli Lilly
Lilly lays out 2-year plan to gain approval for Alzheimer's drug
Study results for donanemab showed signs of slowing disease progression, but the company believes the FDA won't review until another study confirms that apparent benefit.
By Jonathan Gardner • March 15, 2021 -
Courtesy of AstraZeneca
AstraZeneca says 'no evidence' linking vaccine to clots after multiple countries pause rollout
The drugmaker defended its shot following reports of blood clots among vaccine recipients, noting more than 17 million people in the U.K. and Europe have now received it.
By Ben Fidler • March 15, 2021 -
Detailed Lilly data give mixed picture of Alzheimer's drug's benefit
Highly anticipated results from a Phase 2 study of donanemab showed treatment slowed disease progression on one measure, but mixed data on other scales could temper optimism in its potential.
By Jonathan Gardner • March 13, 2021 -
Alex Wong via Getty Images
The top drugs that could be impacted by an obscure provision in the pandemic relief law
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs.
By Jonathan Gardner • March 12, 2021 -
Permission granted by Johnson & Johnson
Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots
The U.S. is now averaging more than 2 million doses given each day, a pace that will help President Joe Biden meet his target of 100 million shots in 100 days well ahead of schedule.
By Ned Pagliarulo • March 11, 2021 -
Courtesy of Eli Lilly
Lilly builds case for COVID-19 drug cocktail with new data
A low-dose combination of Lilly antibodies for COVID-19 reduced deaths and hospitalizations in a Phase 3 trial, a finding that could boost its use.
By Kristin Jensen • March 10, 2021 -
Taking a page from Celgene, Takeda builds and buys a cancer biotech
An agreement to acquire Maverick Therapeutics for up to $525 million has roots in a plan hatched by Takeda to emulate elements of Celgene's dealmaking strategy.
By Ben Fidler • March 9, 2021 -
Permission granted by Novartis
Novartis bid to bring rare disease drug to lung cancer hits a roadblock
Promising signs from a cardiovascular trial had led the Swiss firm to test canakinumab, a drug for rare immune diseases, in lung cancer. But the first test of that theory has failed.
By Jonathan Gardner • March 9, 2021 -
Permission granted by Roche
Spurred by FDA review, Roche pulls Tecentriq for bladder cancer use
Four years after negative study results, the pharma withdrew the indication as the FDA's "industry-wide evaluation" of accelerated approvals progresses.
By Jonathan Gardner • March 8, 2021 -
Courtesy of AstraZeneca
Crucial data on AstraZeneca's vaccine are coming. Here's what we may learn.
Results from previous trials have raised questions about the vaccine and how well it works. Data from a large U.S. study could help clear up the confusion.
By Ben Fidler • March 8, 2021 -
Courtesy of Eli Lilly
Lilly says diabetes shot outperformed rival Novo drug in study
The results are a boost for Lilly's drug, tirzepatide, which is being prepared for regulatory submissions later this year. But long-term heart data won't be available for some time.
By Jonathan Gardner • March 4, 2021 -
Courtesy of Eli Lilly
Lilly drug regrows hair in autoimmune disease study, but safety questions linger
The results could help baricitinib become the first treatment for alopecia areata, a leading cause of hair loss. Safety concerns have diminished the drug's prospects in arthritis, however.
By Ben Fidler • March 3, 2021 -
Merck to help J&J make vaccine doses in White House-brokered deal
The U.S. government will give Merck $269 million to help the drugmaker retool two of its facilities to make J&J's one-dose shot.
By Jonathan Gardner • Updated March 2, 2021 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Merck withdraws Keytruda in type of lung cancer amid 'industry-wide' review by FDA
Since December, three drugmakers have withdrawn immunotherapies from indications previously granted fast-tracked approvals, suggestive of broader FDA concerns.
By Ben Fidler • March 2, 2021 -
Permission granted by Johnson & Johnson
J&J's 1-dose coronavirus vaccine becomes third available in US
A CDC vaccine panel recommended use of the shot on Sunday following FDA authorization, and McKesson began shipping out doses to states Monday.
By Ned Pagliarulo • Updated March 1, 2021 -
AstraZeneca withdraws immunotherapy in bladder cancer after trial failure
The British drugmaker's decision to pull Imfinzi from what was its first approved treatment setting hints at the limitations of immuno-oncology drugs.
By Jonathan Gardner • Feb. 22, 2021 -
Sanofi and GSK start trial of upgraded coronavirus vaccine after first version disappoints
The companies think a new formulation will yield better results than their first attempt. But with several vaccines available, testing may be more challenging.
By Ben Fidler • Feb. 22, 2021 -
Courtesy of BioNTech
Pfizer, BioNTech ask FDA approval to ease temperature requirements for coronavirus shot
Testing showed the vaccine could be safely stored at normal freezer temperatures, rather than the roughly minus 70 degrees Celsius now specified. The change, if cleared by the agency, will help distribution.
By Jonathan Gardner • Feb. 19, 2021 -
Courtesy of Eli Lilly
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
For $125 million up front, Lilly secures rights to a drug about to enter mid-stage testing for autoimmune and inflammatory diseases, as well as preclinical assets targeting the central nervous system.
By Jacob Bell • Feb. 18, 2021
Previous
